top of page


drug development and the PK-Eye


The PK-Eye™ is a compartmentalised, in vitro model that mimics the dimensions and aqueous outflow of the human eye.

Human clearance times for biologics and membrane permeable drugs can be accurately estimated using the PK-Eye™.

The PK-Eye™ accelerates formulation and late preclinical dose escalation studies that are not possible using in vivo and radiolabeled studies.

Use of the PK-Eye™ permits much better resource allocation for the efficient use of in vivo and radiolabeled studies required for optimised developmental candidates.

Optceutics Ltd is able to conduct high throughput formulation development of intraocular drugs at all stages of preclinical development.




S. Awwad at Institute of Ophthalmology Symposium, London, U.K.

Development of novel ocular therapies with the PK-Eye model

B. Butler at ISOPT, Tel Aviv, Israel
The PK-Eye™: Accelerate the development of drugs for the back of the eye


S. Awwad at SDDS, Prague, Czech Republic 
A sustained release intravitreal protein formulation

S. Awwad at EuroPPS, Valencia, Spain
The PK-Eye: the need for an ocular flow model for the development of new therapies

S. Awwad at Global Ophthalmology Summit, London, U.K. 
A new model for developing intravitreal formulations


B. Butler at ISOPT, Rome, Italy 
Introduction: The PK-Eye™, a new tool for Drug Development

S. Awwad, P. T. Khaw and S. Brocchini at Pharmaceutica, Madrid, Spain 
The PK-Eye: A novel in vitro model to evaluate ocular pharmacokinetics


S. Awwad, P. T. Khaw and S. Brocchini at KTN meeting, Cambridge, UK
Extending the therapeutic tail of proteins

S. Awwad, P. T. Khaw and S. Brocchini at UCL, School of Pharmacy Research Day, London, UK 
The PK-Eye: why we need an ocular flow model for the development of new therapies


bottom of page